Table 2.
Demographic and clinical characteristics, Univariate and Multivariate analysis of stroke progression group and nonprogression group.
| Characteristics | Nonprogression group, n = 295 | Progression group, n = 33 | Univariate and Multivariate analysis |
Multivariate analysis |
||||
|---|---|---|---|---|---|---|---|---|
| OR (95%CI) | SE | P value | OR (95%CI) | SE | P value | |||
| Age, y | 67.94 ± 11.12 | 73.27 ± 10.25 | 1.05 (1.01–1.08) | 0.01 | 0.01 | 1.04 (1.00–1.48) | 0.02 | 0.047 |
| Men, n(%) | 203(89.43%) | 24(10.57%) | 0.83 (0.37–1.85) | 0.33 | 0.645 | / | / | / |
| BMI | 24.16 ± 3.10 | 24.3 ± 2.81 | 1.014 (0.90–1.14) | 0.06 | 0.804 | / | / | / |
| TC, mmol/L | 1.54 ± 1.04 | 1.58 ± 1.34 | 1.03 (0.73–1.46) | 0.18 | 0.838 | / | / | / |
| TG, mmol/L | 3.97 ± 1.05 | 4.01 ± 1.00 | 1.03 (0.75–1.42) | 0.16 | 0.857 | / | / | / |
| HDL, mmol/L | 1.13 ± 0.54 | 1.18 ± 0.50 | 1.18 (0.65–2.13) | 0.35 | 0.587 | / | / | / |
| LDL, mmol/L | 2.44 ± 0.88 | 2.40 ± 0.80 | 0.95 (0.63–1.43) | 0.19 | 0.806 | / | / | / |
| Uric acid, μmol/L | 328.85 ± 97.06 | 321.28 ± 95.51 | 1.00 (1.00–1.00) | 0.001 | 0.67 | / | / | / |
| FSG, mmol/L | 6.68 ± 3.14 | 6.88 ± 3.73 | 1.02 (0.92–1.13) | 0.05 | 0.734 | / | / | / |
| HbA1c | 6.74 ± 1.68 | 6.82 ± 1.83 | 1.03 (0.84–1.26) | 0.1 | 0.792 | / | / | / |
| NLR | 4.29 ± 3.26 | 6.28 ± 3.97 | 1.1 (1.05–1.25) | 0.05 | 0.002 | / | / | / |
| Infarction area(cm3) | 730.35(125.96, 3036.36) | 2563.18(683.59, 20474.27) | 1.00 (1.00–1.00) | <0.001 | <0.001 | / | / | / |
| NIHSS scores | 5.80 ± 4.61 | 9.33 ± 6.93 | 1.12 (1.06–1.20) | 0.03 | <0.001 | / | / | / |
| XO, ng/mL | 1.69 ± 0.85 | 2.39 ± 0.80 | 2.49 (1.62–3.83) | 0.54 | <0.001 | 1.98 (1.12–3.50) | 0.57 | 0.018 |
| Hypertension(%) | 222(89.16%) | 27(10.84%) | 1.48 (0.59–3.72) | 0.69 | 0.405 | / | / | / |
| CHD(%) | 39(90.70%) | 4(9.30%) | 0.91 (0.30–2.72) | 0.5 | 0.859 | / | / | / |
| AF(%) | 48(94.12%) | 3(5.88%) | 0.51 (0.15–1.75) | 0.32 | 0.288 | / | / | / |
| Diabetes mellitus(%) | 62(87.32%) | 9(12.68%) | 1.41(0.62–3.19) | 0.58 | 0.41 | / | / | / |
| Family history of cardiovascular and cerebrovascular events (%) | 40(76.92%) | 12(23.08%) | 3.64 (1.66–7.98) | 1.45 | 0.001 | / | / | / |
| Drinking history (%) | 78(90.70%) | 8(9.30%) | 2.62 (1.26–5.48) | 0.98 | 0.01 | 2.48 (1.02–6.02) | 1.12 | 0.044 |
| Smoking history (%) | 71(82.56%) | 15(17.44%) | 0.89 (0.39–2.06) | 0.38 | 0.785 | / | / | / |
| Onset time ≤24 h(%) | 133(90.48%) | 14(9.52%) | 1.09 (0.71–1.66) | 0.23 | 0.691 | / | / | / |
| 24 h–48 h(%) | 73(91.25%) | 7(8.75%) | / | / | / | / | / | / |
| 48 h–72 h(%) | 87(88.78%) | 11(11.22%) | / | / | / | / | / | / |
| TOAST classification, no.(%) | 1.31 (1.02–1.69) | 0.16 | 0.036 | 1.54 (1.08–21.9) | 0.27 | 0.016 | ||
| Large artery | 56(82.35%) | 12(17.65%) | / | / | / | / | / | / |
| Small artery | 127(96.21%) | 5(3.79%) | / | / | / | / | / | / |
| Cardioembolism | 64(88.89%) | 8(11.11%) | / | / | / | / | / | / |
| Other cause | 19(86.36%) | 3(13.64%) | / | / | / | / | / | / |
| Unknown | 29(85.29%) | 5(14.71%) | / | / | / | / | / | / |
BMI, Body mass index; CHD, Coronary heart disease; AF, Atrial fibrillation; TC, Total cholesterol; TG, Triglyceride; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; FSG, Fasting blood glucose; HbA1c, Glycosylated hemoglobin; XO, Xanthine oxidase; NLR, Neutrophil/lymphocyte ratio; NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of ORG 10172 in acute stroke treatment.